Astrazeneca plc(AZN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 12 at 6:40 PM ET (Korea 11/13 08:40)AI-drawn chart patterns are for reference only.
Full metrics table
| Index | - | P/E | 26.09 | EPS (ttm) | 7.07 | Insider Own | 3.44% | Shs Outstand | 1.55B | Perf Week | -1.32% |
| Market Cap | 285.96B | Forward P/E | 16.23 | EPS next Y | 10.7% | Insider Trans | -0.02% | Shs Float | 1.50B | Perf Month | 13.79% |
| Enterprise Value | 312.07B | PEG | 1.45 | EPS next Q | 2.33 | Inst Own | 61.88% | Short Float | 0.2% | Perf Quarter | 17.85% |
| Income | 11.03B | P/S | 4.58 | EPS this Y | 12.04% | Inst Trans | -1.12% | Short Ratio | 0.97 | Perf Half Y | -0.31% |
| Sales | 62.38B | P/B | 5.53 | EPS next 5Y | 11.21% | ROA | 9.41% | Short Interest | 3.03M | Perf YTD | 5.06% |
| Book/sh | 33.36 | P/C | 35.02 | EPS past 3/5Y | 45.9% 22.05% | ROE | 22.6% | 52W High | -13.32% ($212.71) | Perf Year | 4.96% |
| Cash/sh | 5.27 | P/FCF | 27.8 | Sales past 3/5Y | 9.82% 16.31% | ROIC | 13.7% | 52W Low | 20.19% ($153.41) | Perf 3Y | 48.35% |
| Dividend Est. | $3.34 (1.81%) | EV/EBITDA | 14.89 | EPS Y/Y TTM | 17.34% | Gross Margin | 74.11% | Volatility(W/M) | 1.78% 1.84% | Perf 5Y | 55.74% |
| Dividend TTM | 3.23 | EV/Sales | 5 | Sales Y/Y TTM | 7.32% | Oper. Margin | 23.31% | ATR (14) | 4.34 | Perf 10Y | 238.62% |
| Dividend Ex-Date | 2026/8/7 | Quick Ratio | 0.79 | EPS Q/Q | 23.13% | Profit Margin | 17.68% | RSI (14) | 61.84 | Recom | 1.5 |
| Dividend Gr. 3/5Y | 1.78% 3.25% | Current Ratio | 1.01 | Sales Q/Q | 6.7% | SMA20 | 3.52% ($178.11) | Beta | 0.28 | Target Price | $228.71 |
| Payout | 47.19% | Debt/Eq | 0.66 | Earnings | 2026/10/30 | SMA50 | 9.48% ($168.41) | Rel Volume | 0.55 | Prev Close | $185.48 |
| Employees | 96100 | LT Debt/Eq | 0.56 | EPS/Sales Surpr. | 7.91% 1.3% | SMA200 | 2.33% ($180.18) | Avg Volume(3M) | 3.12M | Price | $184.38 |
| IPO | 2003/10/17 | Option/Short | Yes/Yes | Trades | 22617 | Volume | 1,709,506 | Change | -0.59% |
💊 A multinational pharmaceutical company operating a global novel-drug pipeline spanning oncology, cardiovascular, respiratory, and rare-disease therapeutics. It was formed through the 1999 merger of Sweden's Astra and the UK's Zeneca, is headquartered in the UK, and trades on US exchanges through American Depositary Receipts (ADRs).
Over the past 1 year, roughly in the middle
13% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
AZN makes money exceptionally well
Of every $100 in sales, $23.31 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +12.0% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,489. Peers typically go for $1,498.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +55.7%. The S&P 500 did +62% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 1.81% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 61.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #6 of 21 in the industry
Based on market cap of $286B.
MRK#4 Merck & Co Inc $362B PER 150.1 
NVS#5 Novartis AG ADR $293B PER 30.6 
AZN#6 Astrazeneca plc $286B PER 26.1 
AMGN#7 AMGEN Inc $253B PER 27.1 
GILD#8 Gilead Sciences Inc $208B PER - 
FAQ
What kind of company is AZN?
AZN belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of AZN?
The market cap of AZN is approximately $286.0B, ranking 45 within its sector.
Does AZN pay dividends?
AZN has a dividend yield of approximately 1.81%, with an annual dividend of $3.34.
What is the P/E ratio of AZN?
AZN has a P/E ratio of approximately 26.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AZN?
AZN has recorded a 52-week high of $212.71 and a low of $153.41.
